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BAP1 is a deubiquitinase (DUB) of the Ubiquitin C-terminal Hydrolase (UCH) family that
regulates gene expression and other cellular processes, via deubiquitination of histone
H2AK119ub and other substrates. BAP1 is an important tumor suppressor in human,
expressed and functional across many cell-types and tissues, including those of the
immune system. B lymphocytes are the mediators of humoral immune response, however
the role of BAP1 in B cell development and physiology remains poorly understood. Here
we characterize a mouse line with a selective deletion of BAP1 within the B cell lineage
(Bap1fl/fl mb1-Cre) and establish a cell intrinsic role of BAP1 in the regulation of B cell
development. We demonstrate a depletion of large pre-B cells, transitional B cells, and
mature B cells in Bap1fl/flmb1-Cremice. We characterize broad transcriptional changes in
BAP1-deficient pre-B cells, map BAP1 binding across the genome, and analyze the
effects of BAP1-loss on histone H2AK119ub levels and distribution. Overall, our work
establishes a cell intrinsic role of BAP1 in B lymphocyte development, and suggests its
contribution to the regulation of the transcriptional programs of cell cycle progression, via
the deubiquitination of histone H2AK119ub.
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B cells are mediators of the humoral immune response, with crucial roles in the defense against
infections, anti-tumor immunity, allergic response, and autoimmune disorders (1–3). B cell
development takes place in the bone marrow and proceeds through multiple well-characterized
developmental stages, guided by the progressive activation of B cell specific transcriptional
programs and sequential rearrangement of the immunoglobulin loci. The transcriptional
programs of B cell differentiation are controlled by a network of transcription factors E2A, EBF1,org April 2021 | Volume 12 | Article 6264181
Lin et al. BAP1 in B Lymphocyte DevelopmentPAX5, IKAROS, BCL11A, FOXO1, IRF4, IRF8 and others that
work in concert with many histone modifying enzymes and
chromatin remodeling complexes (4–7).
Monoubiquitination of histone H2A (H2AK119ub) is a
highly abundant histone modification, associated with gene
silencing (8, 9). It is primarily deposited on chromatin by the
RING1B subunit of the Polycomb repressive complex 1 (PRC1),
which acts as a major epigenetic regulator of cell identity,
differentiation, and development (9–11). The role of PRC1 in B
cell development and lymphomagenesis is well established (10,
12, 13), and the loss of PRC1 complex components in
conditional knockout mouse models impairs B cell
differentiation and disrupts B cell specific transcriptional
programs (14–19). Several deubiquitinases (DUBs) were shown
to reverse the monoubiquitination of histone H2A, including
BAP1, USP16, MYSM1, USP44, and others (8, 20). However, the
role of these DUBs in the transcriptional regulation of B cell
development is less well understood. Recent studies
demonstrated that MYSM1 and USP16 are essential for B cell
development (17, 21–23), while USP44 and USP21 are
dispensable (24, 25). At the same time, the function of USP16
as a DUB for histone H2A was questioned, given its primarily
cytosolic localization (26). BAP1 is becoming widely recognized
as the major ubiquitously expressed DUB for histone H2A,
however its role in B cell development and physiology remains
poorly explored.
BAP1 is a member of the Ubiquitin C-terminal Hydrolase
(UCH) family of DUB proteins. BAP1 forms a complex with
Polycomb group prote ins ASXL1 and ASXL2, and
deubiquitinates histone H2AK119ub to antagonize PRC1-
mediated gene silencing (27–30). BAP1 also interacts with host
cell factor 1 (HCF1) (31–33), an important transcriptional
regulator of cell proliferation and cell cycle progression (34,
35). BAP1 deubiquitinates and stabilizes HCF1, promoting its
transcriptional activity (31–33, 35), and in complex with HCF1
also regulates the stability and activity of other transcriptional
and metabolic regulators: YY1 (33), KLF5 (36), PGC1a (37), and
OGT (37, 38). BAP1 also interacts with forkhead transcription
factors FOXK1 and FOXK2, and promotes the transcriptional
repression of FOXK2-regulated genes through mechanisms
involving H2AK119ub deubiquitination (39, 40). Beyond its
major multifaceted roles as a transcriptional regulator, BAP1 is
also engaged in the homologous recombination pathway of DNA
repair (41), and can localize to the endoplasmic reticulum to
deubiquitinate and stabilize inositol-1,4,5-trisphosphate-
receptor channel type-3 (IP3R3), modulating Ca2+ release and
cell apoptosis (42).
BAP1 is an important tumor suppressor in human, with
somatic or germinal BAP1 mutations being common in
mesothelioma, uveal melanoma, renal cell carcinoma, and
other cancers (43, 44), while mutations in BAP1 interacting
Polycomb proteins ASXL1/2 are prevalent in myeloid leukemia
(44, 45). In mouse, full systemic loss of BAP1 results in
embryonic lethality at mid-gestation (38), while Bap1+/- mice
develop normally but have increased incidence of sporadic
tumors (46). Importantly, an inducible systemic deletion ofFrontiers in Immunology | www.frontiersin.org 2Bap1 in Bap1fl/flCreERT2 mice resulted in broad spectrum
hematologic pathology, with an expansion of myeloid
leukocytes, and a depletion of platelet and red blood cells,
resembling myelodysplastic syndrome (MDS) and chronic
myelomonocytic leukemia (CMML) (38). These mice also
exhibited impaired thymocyte differentiation and diminished
peripheral T cell expansion, with disruptions in the
transcriptional programs of cell cycle progression in T cells
(47). Importantly, depletion of B cells was also observed
following the systemic inducible deletion of Bap1 in Bap1fl/fl
CreERT2 mice (47). However, this experimental model did not
allow characterization of the cell-intrinsic functions of BAP1 in
the B cell lineage, independently of BAP1 functions in the
precursor hematopoietic stem and progenitor cells (38), and
independently of other cells that interact with B cells to regulate
their maturation and engagement in immune response (47).
Furthermore, BAP1 molecular functions and mechanisms of
action in the B cell lineage were not explored in the previous
studies. The role of BAP1 in B cell development is the focus of
our current work.
Here we characterize the Bap1fl/flmb1-Cremouse strain with a
specific loss of BAP1 within the B cell lineage. Bap1fl/flmb1-Cre
mice showed a systemic reduction in B cell numbers, with a
depletion of large pre-B cells, transitional and mature B cell
subsets, establishing the cell intrinsic role of BAP1 in the
regulation of B cell development. This was associated with a
defect in cell cycle progression in Bap1fl/flmb1-Cre primary pre-B
cells and in Bap1-knockout B cell precursor cell lines. RNA-Seq
analyses of Bap1fl/flmb1-Cre pre-B cells demonstrated a
downregulation of genes involved in cell proliferation and cell
cycle progression, consistent with both the depletion of the
proliferative large pre-B cell subset and impaired cell cycle
progression in BAP1 deficiency. ChIP-Seq analyses in the B
cell precursor cell line Ba/F3 mapped BAP1 binding across the
genome and determined the effects of BAP1 loss on histone
H2AK119ub levels, suggesting a direct role of BAP1 in the
regulation of genes required for normal cell cycle progression,
via its deubiquitinase catalytic activity on histone H2A. Overall,
our study establishes the non-redundant and cell intrinsic role of
BAP1 in the regulation of B cell development.MATERIALS AND METHODS
Mouse Strains
Bap1tm1c(EUCOMM)Hmgu mouse strain carries a floxed (conditional)
allele of Bap1-gene and will be referred to here as Bap1fl. The strain
is derived from ES-cell clone HEPD0526_2_G01; allele structure is
provided at https://www.mousephenotype.org/data/alleles/
MGI:1206586/tm1c(EUCOMM)Hmgu, and the mice are
available from EMMA at: https://www.infrafrontier.eu/search?
keyword=Bap1. Specifically, loxP sites flank exons 6-12
(ENSMUSE00000121807- ENSMUSE00000121801) of the Bap1
transcript ENSMUST00000022458.10. We thank the Wellcome
Trust Sanger Institute Mouse Genetics Project, its funders, and
INFRAFRONTIER/EMMA (www.infrafrontier.eu) for providingApril 2021 | Volume 12 | Article 626418
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mouseportal and associated primary phenotypic information at
www.mousephenotype.org (48–51). The strain was bred to a
transgenic line expressing Cre recombinase under the control of
a B cell lineage specific promoter mb1-Cre (from Prof. Michael
Reth, MPI für Immunbiologie und Epigenetik, Germany) (52).
The Bap1D allele is predicted to disrupt Bap1 protein coding
sequence from amino acid 126 onward, precluding the
expression of full N-terminal UCH catalytic domain and all
downstream domains of BAP1 protein. All lines were on the
C57BL/6 genetic background. The mice were maintained under
specific pathogen-free conditions. Test and control groups were
bred as littermates and co-housed together. Experiments were in
accordance with the guidelines of the Canadian Council on
Animal Care and protocol AUP-2011-6029 approved by the
McGill Animal Care Committee. Mice used in experiments were
both male and female, 8-16 weeks of age, and always age-matched
and sex-matched between the experimental groups. Genotyping
was performed with DreamTaq DNA Polymerase (Thermo Fisher
Scientific) and primers from IDT Technologies.
Bone Marrow Transplantation
For competitive bone marrow transplantations, recipient B6.SJL-
PtprcaPepcb/Boy mice (JAX002014, congenic for CD45.1) were
irradiated with 2 doses of 4.5Gy, delivered 3 hours apart, in a
RS2000 irradiator (Rad Source). Wild-type CD45.1-marked bone
marrow cells were mixed in a 1:1 ratio with bone marrow cells
from mice of Bap1fl/+, Bap1fl/+Cre, or Bap1fl/flCre genotypes, and
the mixes transplanted into three independent cohorts of
recipient mice. The mice were kept on neomycin in drinking
water (2g/l, BioShop) for 3 week, and analyzed at 10 and 17
weeks post-reconstitution.
Flow Cytometry
Cell suspensions of mouse tissues were prepared in RPMI-1640
(Wisent) with 2% (v/v) FCS, 100mg/ml streptomycin and 100U/ml
penicillin (Wisent). The cells were stained for surface-markers in
PBS with 2% FCS for 20 minutes on ice, with the following
antibodies: APC-conjugated anti-CD43 (S7, BD Biosciences) or
anti-IgD (11-26c.2a, BioLegend); APC-eFluor 780-conjugated
anti-CD45R/B220 (RA3-6B2, eBioscience) or anti-CD45.1 (A20,
eBioscience); Brilliant Violet 650-conjugated anti-CD45R/B220
(RA3-6B2, BioLegend); BUV395-conjugated anti-CD43 (S7, BD
Biosciences); eFluor 450-conjugated anti-CD24 (M1/69,
eBioscience) or anti-CD45R/B220 (RA3-6B2, eBioscience);
FITC-conjugated anti-CD23 (B3B4, eBioscience), anti-CD127/
IL7Ra (A7R34, eBioscience), or anti-CD249/BP-1 (6C3,
eBioscience); Pacific Blue-conjugated anti-IgD (11-26c.2a,
BioLegend); PE-conjugated anti-IgM (II/41, eBioscience); PE-
Cy7-conjugated anti-CD19 (6D5, BioLegend), anti-CD21/CD35
(eBio8D9, eBioscience), anti-CD93 (AA4.1, BioLegend), or anti-
CD45.2 (104, BioLegend); PerCP-Cy5.5-conjugated anti-CD19
(1D3, Tonbo Biosciences), anti-CD93 (AA4.1, BioLegend), or
anti-CD45R/B220 (RA3-6B2, BioLegend); biotin conjugated
anti-Pre-B Cell Receptor (SL156, BD Biosciences).
Intracellular staining was performed as previously described
(53, 54). The cells were fixed in 2% paraformaldehyde (PFA) inFrontiers in Immunology | www.frontiersin.org 3PBS with 2% FCS at 37°C for 10 minutes, and permeabilized in
90% methanol for 30 minutes on ice. The cells were then stained
with Alexa Fluor 647-conjugated anti- p53 (1C12, Cell Signaling
Technology) and Alexa Fluor 488-conjugated anti-H2A.X
Phospho (Ser139) (2F3, BioLegend) antibodies, or FITC-
conjugated anti-Ki-67 (B56, BD Biosciences) and Alexa Fluor
647-conjugated Histone H3 Phospho (Ser10) (11D8, BioLegend)
antibodies, or the appropriate isotype controls. Viability Dye
eFluor® 506 (eBioscience) was used to discriminate dead cells.
Annexin V PeCy7 (eBioscience) was used for detection of
apoptotic cells. Compensation was performed with BD™
CompBeads (BD Biosciences). The data were acquired on
FACS Canto II or BD Fortessa and analyzed with FACS Diva
(BD Biosciences) or FlowJo (Tree Star) software.
B Cell Isolation and Cell Sorting
Total B cells were isolated from mouse spleen via magnetic
enrichment using EasySep Mouse CD19 Positive Selection Kit II
(Stem Cell Technologies), according to the manufacturer’s
protocols. B cell subsets were sorted from mouse bone marrow,
as previously described (53). Bone marrow was flushed in PBS
supplemented with 0.1% BSA and 2mM EDTA, filtered through
40mm cell-strainers, and subjected to red blood cell lysis in ACK
buffer (0.15M NH4Cl, 10mM KHCO3, 0.1mM EDTA). The
samples were stained with: biotin-conjugated antibodies
against lineage markers [anti-CD3ϵ (145-2C11, BioLegend),
anti-CD11b (M1/70, BioLegend), anti-CD11c (N418,
BioLegend), anti-Ly-6G/Ly-6C (Gr-1) (RB6-8C5, BioLegend),
anti-NK-1.1 (PK136, BioLegend), and anti-TER-119 (TER-119,
BioLegend)], followed by APC-eFluor 780-conjugated
Streptavidin (eBioscience), Alexa Fluor 488-conjugated anti-
IgD (11-26c.2a, BioLegend), APC-conjugated anti-CD43 (S7,
BD Biosciences), PE-conjugated anti-IgM (II/41, eBioscience),
PE-Cy7-conjugated anti-CD19 (6D5, BioLegend), and PerCP-
Cy5.5-conjugated anti-CD45R/B220 (RA3-6B2, BioLegend)
antibodies. DAPI was added immediately before sorting for
dead cell exclusion. Cell sorting was performed on FACSAria
and analyzed with FACS Diva software (BD Biosciences).
Pre-B Colony Forming Unit (CFU) Assays
Pre-B Colony Forming Unit (CFU) assays with primary mouse
bone marrow were performed according to manufacturer’s
protocols using MethoCult M3630 media (StemCell
Technologies), with 1x105 mouse bone marrow cells plated
per dish.
Western Blotting
Western blotting was performed as previously described (53).
Magnetically isolated murine B cells were lysed in RIPA buffer
supplemented with protease and phosphatase inhibitors
(Thermo Scientific). Protein concentration was measured using
the BCA assay (Thermo Scientific). Protein lysate samples were
boiled in Laemmli buffer and 1.25% b-mercaptoethanol (Sigma-
Aldrich) before loading onto gels, alongside Precision Plus
Protein Kaleidoscope standards (Bio-Rad). Upon gel-to-
membrane transfer, nitrocellulose membranes (GE Healthcare)
were blocked with 5% milk in TBS-T and probed with rabbitApril 2021 | Volume 12 | Article 626418
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Signaling Technology) and b-Actin (D6A8, Cell Signaling
Technology) at 4°C overnight, followed by horseradish
peroxidase (HRP)-conjugated goat anti-rabbit polyclonal IgG
secondary antibody (Abcam) at room temperature for 1 hour,
with TBS-T washes after each antibody-incubation. Protein
bands were detected using Western Lightning Plus-ECL
(PerkinElmer) and HyBlot CL autoradiography films (Harvard
Apparatus Canada), according to manufacturer’s protocol.
RNA Isolation and qRT-PCR
RNA isolation from magnetically isolated B cells was carried out
with the EZ-10 DNAaway RNA mini-prep kit (BioBasic)
according to the manufacturer’s protocol. The RNA was
quantified with Nanodrop spectrophotometry (ThermoFisher
Scientific), and reverse transcribed with the M-MLV reverse-
transcription kit (Life Technologies, ThermoFisher Scientific).
All qPCRs were performed on a StepOnePlus instrument with
Power SYBR Mastermix (Appl ied Biosystems, Li fe
Technologies). The primer sequences for validating Bap1-
depletion in murine B cells were: Bap1 -Fw GGA TTG AAA
GTC TAC CCA ATT GAT, Bap1 -Rv CGA GCT TTA TCT GTC
CAC TCC T, Actb -Fw CTA AGG CCA ACC GTG AAA AG,
Actb -Rv ACC AGA GGC ATA CAG GGA CA; all primers were
purchased from IDT Technologies.
Cell Culture
Murine B cell lineage precursor cell line Ba/F3 was maintained at
0.5-2 x106 cells/mL in RPMI-1640 (Wisent) with 10% Fetal Calf
Serum (FCS, Wisent), 2mM L-Glutamine, 100mg/mL
streptomycin, 100U/mL penicillin (Wisent), and 5% WEHI
conditioned media as the source of IL-3. Ba/F3 cell lines stably
expressing triple-FLAG-tagged murine BAP1 were derived as
previously described (53), and maintained under 2mg/mL
puromycin selection (Wisent).
CRISPR-Cas9 Gene Targeting
Plasmid pSpCas9(BB)-2A-GFP (PX458) was obtained from
Addgene (#48138). gRNAs targeting Bap1 were designed using
the Zhang lab software (http://crispr.mit.edu): gRNA_
Bap1_Exon4_ Chr14:32,066,155: gcaaatggatcgaagagcgc and
gRNA_Bap1_Exon5_Chr14:32,066,654: ggcgtgagtggcacaagagt.
The gRNAs were ligated into the BbsI (NEB) digested PX458
plasmid, and the resulting plasmids were transformed into
DH5a competent cells, purified using PureLink HiPure
Plasmid Filter Midiprep Kit (Invitrogen), and verified by
Sanger sequencing. To introduce the constructed plasmid into
Ba/F3 cells, nucleofection was performed using Amaxa Cell Line
Nucleofector Kit V (Lonza) according to the manufacturer’s
protocols. Single GFP+ cells were sorted 48 hours after the
nucleofection and then expanded over two weeks to generate
single cell clones. The loss of BAP1 protein expression in the cell
line clones was validated viaWestern blotting, with the following
antibodies: anti-BAP1 (D7W7O, Cell Signaling Technology),
anti-b-Actin (D6A8, Cell Signaling Technology), HRP-
conjugated anti-mouse-Ig (eB144, Rockland), and HRP-
conjugated anti-rabbit-Ig (eB182, Rockland).Frontiers in Immunology | www.frontiersin.org 4AlarmarBlue Assay
Wildtype and Bap1D/D Ba/F3 cells were seeded into a 96-well
plate at a density of 1 × 105/mL, and incubated at 37°C overnight.
Subsequently, AlamarBlue (Invitrogen, Thermo Fisher Scientific)
was added at 1/10 the total volume to each well and incubated at
37°C for 4 h. Fluorescence intensity was recorded using an
EnSpire Plate reader (Perkin Elmer), at the excitation
wavelength of 560nm and the emission wavelength of 590nm.
CFSE Cell Proliferation Assay
Wildtype and Bap1D/D Ba/F3 cells were washed with PBS, and
5 × 106 cells were resuspended in 1 ml PBS containing 1 ml
CellTrace™ CFSE/DMSO solution (Invitrogen, Thermo Fisher
Scientific). After 10 min of incubation at 37°C, CFSE was
deactivated by adding 12 mL pre-warmed PBS with 5% FBS
and incubation at 37°C for 5 min, followed by centrifugation and
a second wash with PBS. Subsequently, cells were resuspended in
complete culture media at the concentration of 2 × 105/mL,
seeded in a 96-well plate at 4 x104 cells per well, and incubated at
37°C overnight. The cells were counterstained with Fixable
Viability Dye eFluor™ 780 (eBioscience, Thermo Fisher
Scientific). Fluorescence intensity data was acquired on FACS
Canto II and analyzed with FACS Diva (BD Biosciences) or
FlowJo (Tree Star) software.
RNA Sequencing (RNA-Seq)
The protocols were as previously described (53). Briefly, RNA
was isolated using the MagMAX total RNA kit (Ambion, Life
Technologies), and quality assessed using Bioanalyzer RNA Pico
chips (Agilent). rRNA depletion and library preparation were
performed using the SMARTer Stranded RNA-Seq kit (Takara
Clontech). The libraries were sequenced on an Illumina HiSeq
4000 sequencer in paired-end 50bp configuration. The high
quality of sequence reads was confirmed using the FastQC tool
(Babraham Bioinformatics), and low-quality bases were trimmed
from read extremities using Trimmomatic v.0.33 (55). Reads
were then mapped to the mouse UCSC mm9 reference assembly
using TopHat v2.0.9 in conjunction with Bowtie 1.0.0 algorithm
(56–58). Gene expression was quantified by counting the
number of uniquely mapped reads with featureCounts using
default parameters (59). We retained genes that had an
expression level of minimum 5 counts per million reads
(CPM) in at least 3 of the samples, and performed quantile
normalization with the preprocessCore package to remove batch
effects (60). TMM normalization and differential gene expression
analyses were conducted using the edgeR Bioconductor package
(61). Dimension reduction analysis was performed using the
Partial Least Square regression method (62). Pairwise
comparisons were performed between samples across different
mouse genotypes. Genes with changes in expression ≥ |1.5| fold
and Benjamini-Hochberg adjusted p values ≤ 0.01 across the
three genotypes in either pre-B or immature B cells were
considered significant. For data visualization in Integrative
Genomics Viewer (IGV) (63), replicates with the same
genotype were combined, and bigwig files were generated using
a succession of genomeCoverageBed and wigToBigWig tools andApril 2021 | Volume 12 | Article 626418
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and disease ontology enrichment analyses on differentially
expressed gene clusters were performed with DAVID
Bioinformatics Resources 6.8 (64), and Gene Set Enrichment
Analysis (GSEA) was performed in command-line using
MSigDB v6.0 with default configuration and permutation
within gene sets (65).
Chromatin Immunoprecipitation (ChIP)
ChIP was performed as described previously (66), with minor
modifications. Briefly, cells were fixed with 1% formaldehyde in
the culture media for 10 minutes at room temperature, followed
by addition of 0.125M of glycine to stop fixation. Nuclei were
extracted with 5 minutes lysis in 0.25% Triton buffer, followed by
30 minutes in 200mM NaCl buffer. Nuclei were resuspended in
sonication buffer and sonicated for twelve cycles of 30 seconds
with a digital sonifier (Branson Ultrasonics) at 80%, with 30
seconds rest in cooled circulating water.
Beads immunocomplexes were prepared overnight by
conjugating 40mL of Dynabeads Protein G (Invitrogen, Life
Technologies) with antibodies: anti-BAP1 (Cell Signaling
Technology, D1W9B, 52.8 mg), anti-FLAG M2 (Sigma, F1804,
5 mg) or anti-H2AK119Ub (Cell Signaling Technology, D27C4,
5 mg). Immunoprecipitation was performed by overnight
incubation of antibody-bead matrices with sheared chromatin
from the equivalent of 5x106 cells. Four washes were performed
with medium-stringency buffers for BAP1-FLAG ChIP, while six
washes were performed with low-stringency buffers for histone
ChIP and ChIP using the anti-BAP1 antibody (Cell Signaling
Technology). Samples were de-crosslinked by overnight
incubation at 65°C in 1% SDS buffer, and following RNaseA
and Proteinase K enzymatic treatments, ChIP DNA was purified
using Qiaquick PCR Cleanup kit (Qiagen).
ChIP-seq libraries were prepared using the Illumina TruSeq
kit and sequenced on an Illumina HiSeq 4000 sequencer in
paired-end 50bp configuration, with input DNA from the same
cells sequenced as negative control. The reads were mapped to
the UCSC mouse mm9 reference genome with Bowtie 1.0.0 (57),
and BAP1 binding sites identified using peak detection algorithm
MACS1.4 (67), with comparisons for read enrichment against
control input DNA from the same cells. Normalized sequence
read density profiles (bigwig) were generated with Homer tool
(68) and visualized with IGV (63). Gene ontology (GO)
enrichment analyses on genes associated with BAP1 ChIP-Seq
binding clusters were performed on GREAT 4.0.4 (69) with Basal
plus extension option, searching for genes within 2kb upstream,
2kb downstream, and 200kb in distal.
ChIP-Seq and RNA-Seq Data
Consolidation
Full gene annotations with transcription start site (TSS) were
obtained from the UCSC mouse mm9 reference genome. An in-
house Python script was developed to load the genomic locations
of ChIP-Seq binding sites and the TSS locations of RNA-Seq
dysregulated genes, and search for gene TSS located within a
specific distance to each ChIP-Seq binding site. RNA-Seq andFrontiers in Immunology | www.frontiersin.org 5ChIP-Seq datasets acquired and described in our study have been
deposited into the NCBI public database and are available under
GEO Submission GSE162085.
Statistical Analyses
Statistical analyses used Prism 7.01 (GraphPad Inc.), with
Student’s t-test for two datasets and ANOVA with Sidak’s or
Tukey’s post hoc tests for multiple comparisons.RESULTS
Cell Intrinsic Role of BAP1 in
B Lymphocyte Development
To study the role of BAP1 in the B cell lineage, a B cell specific
conditional knockout mouse model was generated by crossing
the Bap1-floxed mouse line Bap1fl/fl to the mb1-Cre line
expressing Cre-recombinase under the control of the B cell
lineage specific Cd79a gene promoter, from the pre-pro-B cell
stage in development (52). As expected, Bap1fl/fl Cre offspring
were born in normal Mendelian ratios, showed no gross
morphological abnormalities, and bred normally. Loss of BAP1
transcript and protein expression was validated in B cells isolated
from the spleen of Bap1fl/fl Cre and control mice, using qRT-PCR
and Western blotting, respectively (Figures 1A, B).
To assess the effects of BAP1-loss on the B cell lineage, spleens
and mesenteric lymph nodes of Bap1fl/fl Cre, Bap1fl/+ Cre, and
control Bap1fl/+ mice were analyzed by flow cytometry, gating on
CD19+ B cells. A significant reduction in the frequency of B cells
was observed in the Bap1fl/fl Cre relative to control mice in
both tissues (Figures 1C–E). The absolute numbers of B cells
were also significantly reduced in the spleen of Bap1fl/fl Cre mice
and showed a trend toward reduction in the lymph nodes
(Figures 1C–E).
We further confirmed the depletion of CD19+B220hi B2
lymphocytes in the spleen of Bap1fl/fl Cre mice, while
CD19+B220lo cells were strongly expanded (Supplemental
Figures S1A–C). Further analysis of the CD19+B220lo B cell
population identified the expected B1b (CD43+CD5-) and B1a
(CD43+CD5+) subsets in control mice, while in Bap1fl/fl Cremice
the majority of the cells lacked B1 markers expression (CD43-
CD5-, Supplemental Figures S1D, E) (70, 71). Overall, we
observed a mild depletion of B1b cells (CD19+B220lo
CD43+CD5-) and expansion of B1a cells (CD19+B220lo
CD43+CD5+) in Bap1fl/fl Cre mice (Supplemental Figures
S1D, E), while the identity of the CD19+B220loCD43- B cells
that are strongly expanded in Bap1fl/fl Cre mice remains to be
further investigated.
Splenic B cells were further analyzed to quantify transitional,
follicular (FOL), and marginal zone (MZ) cell populations
(Supplemental Figure S2) (72). This demonstrated a
significant reduction in the numbers of transitional T2-3,
follicular FOLI-II, and marginal zone progenitor (MZP) B cells
in Bap1fl/fl Cre relative to control mice, while the numbers of
transitional T1 and MZ B cells were maintained (Supplemental
Figure S2).April 2021 | Volume 12 | Article 626418
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chimeric mouse model was established. Wild-type CD45.1+
marked bone marrow cells were mixed in a 1:1 ratio with bone
marrow cells from CD45.2+ mice of Bap1fl/+, Bap1fl/+Cre, or
Bap1fl/flCre genotypes, and the three mixes transplanted into
three independent cohorts of lethally irradiated recipient mice to
reconstitute their immune system (Supplemental Figure S3A).
The recipient mice were analyzed for the relative contribution of
CD45.1+ and CD45.2+ donors to the B cell lineages, by testing the
blood at 10 weeks, and the bone marrow and spleen at 17 weeks
post-reconstitution. Reduced contribution of the BAP1-deficientFrontiers in Immunology | www.frontiersin.org 6Bap1fl/flCre donor cells to the B cell lineage was demonstrated in
all the tissues (Supplemental Figures S3B–E, Supplemental
Figure S4A), further confirming the cell intrinsic role of BAP1
in B cells.Loss of BAP1 Impairs B Cell Development
at the Pre-B Cell Stage in the Bone
Marrow
To analyze the impact of BAP1 loss on B cell development and to




FIGURE 1 | Loss of BAP1 and depletion of B cells in the Bap1fl/fl Cre mouse model. (A) Reduced Bap1 transcript levels in B cells magnetically isolated from the
total splenocytes of Bap1fl/fl Cre, relative to control mice, analyzed by RT-qPCR. Transcript levels are normalized to b-actin, and expressed relative to the transcript
levels in control B cells. Data is from 4 mice per group; bars represent mean ± SEM; statistical analysis by ANOVA, **p < 0.01, ****p < 0.0001. (B) Loss of BAP1
protein in B cells magnetically isolated from the total splenocytes of Bap1fl/fl Cre relative to control mice, analyzed by Western blotting, using b-actin as the loading
control; data from one mouse per genotype. (C–D) Depletion of B cells in the spleen (C) and mesenteric lymph nodes (D) of Bap1fl/fl Cre relative to control mice,
expressed as the percentage of CD19+ cells within the total live cells from the tissue and as the absolute cell number. Data presented is from two experiments with 4
mice analyzed per group per experiment. Bars represent mean ± SEM; statistical analysis by ANOVA, NS non-significant, *p < 0.05, ***p < 0.001. (E) Representative
flow cytometry density plots of the spleen (top) and mesenteric lymph nodes (bottom) stained for B cell lineage markers B220 and CD19, and gated on live cells.
CD19+ B cell gate is shown and the percentage of cells within the gate for each mouse genotype is presented as mean ± S.D.April 2021 | Volume 12 | Article 626418
Lin et al. BAP1 in B Lymphocyte DevelopmentBAP1, the bone marrow of Bap1fl/flCre and control mice was
analyzed by flow cytometry. This demonstrated a significant
reduction in the frequency of B cells in the Bap1fl/flCre relative to
control mice (gated as B220+, Figures 2A–D). The defect in B
cell development in Bap1fl/flCremice was further confirmed with
a colony forming units (CFU) assay, demonstrating a reduction
in the numbers of pre-B CFUs in Bap1fl/flCre bone marrow
samples (Figure 2E). Further characterization of B cell
progenitor subpopulations demonstrated a significant depletion
in the frequencies and absolute numbers of large pre-B cells and
mature B cells, and an expansion of Fraction B pro-B cells in
Bap1fl/flCre relative to control bone marrow (Figures 2F, G). No
changes in the abundance of the common lymphoid progenitors,
multipotent progenitors, and hematopoietic stem cells were
observed (data not shown), further confirming the specificity
of the Cre transgene and the phenotype to the B cell lineage.
Overall, our findings indicate the cell intrinsic role of BAP1 as a
regulator of B cell development, and demonstrate that BAP1 loss
impacts pre-B cells, as well as transitional and mature B
cell subsets.
Impaired Cell Viability and Cell Cycle
Progression in BAP1-Deficient Pre-B Cells
To assess how the loss of BAP1 affects B cell development and
physiology, we analyzed the effects of BAP1 loss on cell viability
and cell cycle progression throughout the B cell lineage, with
flow cytometry. This demonstrated a specific reduction in
the viability of large pre-B cells, caused by an increase in the
proportion of late apoptotic/necrotic cells within this B cell
subset (Figures 3A–B).
To further analyze the effects of BAP1 loss on cell cycle
progression, bone marrow samples from Bap1fl/flCre and control
mice were stained for Ki67 and histone H3S10p, to identify cells
in G0 (Ki67-H3S10p-), G1-S-G2 (Ki67+H3S10p-), and M
(Ki67+H3S10p+) phases of the cell cycle within each B cell
subpopulation. This revealed a significant increase in the
fraction of G0 cells and a corresponding decrease in G1-S-G2
cells within the large pre-B cell, small pre-B cell, immature, and
mature B cell subpopulations in Bap1fl/flCremice (Figures 3C, D,
Supplemental Figures S4B, C), indicating impaired cell
proliferation and cell cycle progression. In contrast no
differences were observed in the cell cycle state of pre-pro-B
and pro-B cells (Figure 3C). Overall, this indicated that impaired
cell survival and proliferation contribute to the depletion of pre-
B cells and possibly to the broader defect in B cell lineage
development in Bap1fl/flCre mice.
We further observed a reduction in the expression of IL7Ra
on the surface of large pre-B cells, but not other B cell precursor
subsets in Bap1fl/flCre relative to control mice (Supplemental
Figures S5A, B), while the expression of pre-B cell receptor (pre-
BCR) on large and small pre-B cells was unchanged
(Supplemental Figures S5C, D). Subsequent RNA-seq
analyses of Bap1fl/flCre and control pre-B cells (Figure 4),
showed no difference in the expression of Il7r gene or
surrogate light chain gene Igll1 in Bap1fl/flCre pre-B cells
(Table S1A, B, Vpreb1-2 did not reach >5CPM expressionFrontiers in Immunology | www.frontiersin.org 7threshold for quantification). This indicates that the differences
in IL7Ra protein expression on pre-B cell surface are likely
mediated via indirect mechanisms, and are not a result of direct
regulation of its encoding gene by BAP1.
Given the previously reported roles of BAP1 not only in
transcriptional regulation but also in DNA repair (41), we
further analyzed the B cell precursor cell populations in the
bone marrow of Bap1fl/flCre and control mice for the levels of
gH2AX as a marker of DNA damage (73) and p53 protein as a
marker of DNA damage response activation (74). There were no
differences in the levels of gH2AX or p53 between Bap1fl/flCre
and control cells for any of the B cell precursor cell populations
(Supplemental Figure S6). This suggested that the role of BAP1
as a regulator of B lymphocyte development is likely independent
of its functions in DNA repair and is primarily linked to its role
as a transcriptional and epigenetic regulator of gene expression.
RNA-Seq Analysis of BAP1-Deficient
B Cell Precursors
To further understand the functional impact of BAP1 loss on B
cell development, RNA-Seq gene expression analysis was
conducted on live pre-B and immature B cells, isolated from
the bone marrow of Bap1fl/flCre, Bap1fl/+Cre, and control Bap1fl/+
mice through FACS-sorting (Figure 4A, Table S1A, B). Loss of
Bap1fl exon expression was confirmed in Bap1fl/flCre datasets
(Supplemental Figure S7A). Dimension reduction analysis of
gene expression profiles showed clear segregation of the two cell
types (PC1 - 46.5% variance) and the three genotypes (PC2 -
9.3% variance, PC3 - 5.6% variance), and indicated major
transcriptional changes in the BAP1-deficient cells (Figure
4B). To explore the biological functions dysregulated within
the transcriptome of BAP1-deficient B cells, a gene set
enrichment analysis (GSEA) (65) was performed and
highlighted the dysregulation of the transcriptional signatures
linked to “cell proliferation”, “DNA replication”, and “cell
division”, as well as many other biological processes in Bap1fl/fl
Cre cells (Figure 4C, Table S1C).
Differential gene expression analysis across the three Bap1
genotypes was performed, at fold change ≥1.5 and false discovery
rate (FDR) ≤0.01. This identified 916 genes significantly
dysregulated in Bap1fl/flCre relative to control Bap1fl/+ cells
(Figure 4D, Table S1A, B). In contrast, in Bap1fl/+Cre cells the
downregulation of Cd79a was the only transcriptional change to
reach the significance threshold, and is likely due to the direct
effect of Cre knockin on the Cd79a locus (52). This demonstrates
the very limited effects of Cre or heterozygous Bap1 loss on the
transcriptome, and confirms that the major transcriptional
changes in Bap1fl/flCre are due to the loss of BAP1 function.
The dysregulated genes were segregated into Clusters I-VI,
based on their upregulation or downregulation status in
Bap1fl/flCre versus control samples across the two cell types
(Figure 4D). Gene ontology (GO) enrichment analysis was
performed for the genes in each cluster, to explore the biological
functions dysregulated in the BAP1-deficient B cell precursors.
The upregulated transcriptional signatures, represented by
Clusters I-III, showed a mild enrichment for GO-termsApril 2021 | Volume 12 | Article 626418





FIGURE 2 | BAP1 loss impairs B cell development from the pre-B cell stage in the bone marrow. (A, B) Representative flow cytometry plots of the bone marrow of mice of
Bap1fl/+, Bap1fl/+Cre, and Bap1fl/flCre genotypes, demonstrating: (A, top) gating on B cell lineage cells (B220+); (A, bottom) gating on mature B cells (IgM+IgD+) and immature
B cells (IgM+IgD-); (B, top) gating on pre-B cells (B220+IgM-IgD-CD43-); (B, bottom) gating on Hardy Fractions A, B and C cells as B220+IgM-IgD-CD43+, followed by CD24
and BP1 markers. Numbers indicate mean ± S.D. of cell frequency in each gate; data is from 10-12 mice per genotype, consolidated across 3 independent experiments.
(C) Representative flow cytometry histograms gated on B220+IgM-IgD-CD43- pre-B cells, and showing the gating on large and small pre-B cell subsets based on the forward
scatter (FSC) of the cells. Numbers indicate mean ± S.D. of cell frequency in each gate; data is from 10-12 mice per genotype, consolidated across 3 independent
experiments. (D) Reduced frequency of B lineage cells (B220+) in the bone marrow of Bap1fl/flCre relative to control mice. Data is from 10-12 mice per genotype, consolidated
across 3 independent experiments. (E) Reduction in pre-B cell colony forming units in the bone marrow of Bap1fl/flCre relative to control mice, demonstrating impaired B cell
lineage development; colony count is presented per 1x105 mouse bone marrow cells plated per dish; 3 mice were analyzed in total in 2 independent experiments.
(F, G) Frequencies and absolute numbers of B cell precursor subpopulations in the bone marrow of Bap1fl/flCre and control mice; the cells were gated as live B220+ cells
followed by IgM-IgD-CD43+CD24loBP1lo for Fraction A, IgM-IgD-CD43+CD24+BP1lo for Fraction B, IgM-IgD-CD43+CD24+BP1+ for Fraction C, IgM-IgD-CD43-FSChi for large
pre-B cells, IgM-IgD-CD43-FSClo for small pre-B cells, IgM+IgD- for immature B cells, and IgM+IgD+ for mature B cells. Bars represent mean ± SEM; flow cytometry data is
from 10-12 mice per genotype, consolidated across 3 independent experiments, with cell counts presented per one tibia and femur. Statistical analyses were performed with
ANOVA; *p < 0.05, **p < 0.01, ****p < 0.0001.Frontiers in Immunology | www.frontiersin.org April 2021 | Volume 12 | Article 6264188
Lin et al. BAP1 in B Lymphocyte Development“immune system process”, “cell migration” and “apoptotic
process” (Figure 4E, Supplemental Table S1D). As an
example the upregulated genes included several receptors for
chemokines and other messengers (Cxcr7, Cxcr5, Cr2, IL2rg, Il9r,
S1pr3, CD40, Ahr), some pattern recognition receptors (Tlr1,
Tlr9, Naip5, Clec12a), transcriptional regulators involved in
immune cell development and activation (Irf5, Irf7, Irf8,
Nfkb2), both pro-survival and pro-apoptotic Bcl-family
proteins (Bcl2, Bbc3), and some oncogenes (Myc). In contrast,Frontiers in Immunology | www.frontiersin.org 9the downregulated transcriptional signature of BAP1-deficient
pre-B cells (Cluster V) showed a highly significant enrichment of
GO-terms “cell cycle progression” and “DNA replication”
(Figure 4E, Supplemental Table S1D), indicating the
downregulation of genes involved in cell proliferation and cell
cycle progression. This is consistent with the depletion of the
highly proliferative large pre-B cell subset within the cell
population (Figures 2F, G), but also with the previously
reported functions of BAP1 in the regulation of transcriptionalA
B D
C
FIGURE 3 | Impact of Bap1-deficiency on the B cell lineage cell viability and cell cycle progression. (A, B) Impaired viability of large pre-B cells in Bap1fl/flCre mice.
Bone marrow and splenocytes of mice of Bap1fl/+ and Bap1fl/flCre genotypes were stained with Annexin V to identify apoptotic cells and with Viability Dye V506
(eBioscience) to identify necrotic cells, as well as for cell surface markers to identify mature splenic B cells (B220+IgM+IgD+), transitional splenic B cells
(B220+IgM+IgD-), immature bone marrow B cells (B220+IgM+IgD-), small pre-B cells (B220+IgM-IgD-CD19+CD43-FSClo), large pre-B cells (B220+IgM-IgD-
CD19+CD43-FSChi), pro-B cells (B220+IgM-IgD-CD19+CD43+), and pre-pro-B cells (B220+IgM-IgD-CD19-CD43+). (A) Frequency of live (AnxV-V506-), early apoptotic
(AnxV+V506-), and late apoptotic/necrotic (AnxV+V506+) cells within each B cell subpopulation in Bap1fl/flCre and control mice. Bars represent mean ± SEM; n=4
mice were analyzed per genotype in total over two independent experiments; statistical analysis used ANOVA, *p < 0.05. (B) Representative flow cytometry density
plots, gated on the large and small pre-B cells and showing the reduced frequency of live cells and increased frequency of late apoptotic/necrotic cells for the large
pre-B cells in Bap1fl/flCre mice. Cell frequency in each gate is indicated as mean ± S.D. (C, D) Impaired cell-cycle progression in Bap1fl/flCre B cells. Bone marrow of
mice of Bap1fl/+, Bap1fl/+Cre, and Bap1fl/flCre genotypes was stained for Ki67 and histone H3S10p, to identify G0 (Ki67-H3S10p-), G1-S-G2 (Ki67+H3S10p-), and M
phase (Ki67+H3S10p+) cells. (C) Frequency of G0, G1-S-G2, and M phase cells within each B cell subpopulation, showing impaired cell cycle progression from the
pre-B stage in development onward in Bap1fl/flCre mice. Bars represent mean ± SEM; n=4 mice were analyzed per genotype in total over two independent
experiments; statistical analyses were performed using ANOVA; *p < 0.05, ***p < 0.001, or not significant if not indicated. (D) Representative flow cytometry density
plots, gated on large and small pre-B cells and showing elevated frequency of G0 cells and reduced frequency of G1-S-G2 cells in Bap1fl/flCre mice; cell frequency in
each gate is indicated as mean ± S.D.April 2021 | Volume 12 | Article 626418
Lin et al. BAP1 in B Lymphocyte Developmentprograms of cell cycle progression in other cell types (32, 34–36,
47). Overall, we hypothesize that a disruption in cell proliferation
and cell cycle progression may contribute to the defects in B cell
development in BAP1-deficiency.Impaired Cell Proliferation in BAP1-
Deficient B Cell Precursor Cell Lines
To further analyze the impact of BAP1 loss on B cell survival and
proliferation and the molecular mechanisms involved, Bap1 gene
was targeted with CRISPR/Cas9 in the B cell precursor cell line Ba/
F3. Two gRNAs were designed to target Bap1 exons 4 and 5 that
encode the key N-terminal catalytic domain of the protein (Figure
5A). Cell clones were screened by PCR for deletions within the
Bap1 locus, and six clones were selected and further analyzed byFrontiers in Immunology | www.frontiersin.org 10Western blotting to confirm the loss of BAP1 protein (Figure 5B).
There was no defect in the viability of Bap1D/D cell lines, as
demonstrated by equivalent frequencies of live, early apoptotic,
and late apoptotic/necrotic cells between the Bap1D/D and control
cell cultures (Figure 5C). The effect of BAP1 loss on the
proliferation of the B cell lines was further analyzed with two
approaches: a colorimetric alamarBlue assay conducted in bulk cell
population, and a flow cytometric CFSE-dilution assay providing
proliferation data at single cell resolution. Both approaches
demonstrated a reduction in cell proliferation for all the Bap1D/D
clones tested, reaching statistical significance for the majority of
the clones (Figures 5D–F). This further confirmed the role of
BAP1 in the regulation of B cell proliferation, and indicated the






FIGURE 4 | RNA-Seq analysis of the transcriptome of Bap1-deficient pre-B and immature B cells. Data presented is from 3-4 mice per genotype. (A) Schematic
representation of the mouse genotypes and cell sorting protocols for the RNA-Seq experiment. (B) 3D principal component analysis model demonstrating the gene
expression profiles of each RNA-Seq sample: differences between cell types are described by principal component 1 (PC1, 46.5% variability) and differences
between genotypes are described by PC2 and PC3 (9.3% and 5.6% variability, respectively). (C) Normalized enrichment scores (NES) of 4,436 pre-established
biological processes expression signatures used in the gene set enrichment analysis (GSEA). (D) Heat map displaying 916 significantly dysregulated genes when
comparing Bap1fl/flCre and control Bap1fl/+ cells. The significance threshold is: fold change ≥ 1.5 and False Discovery Rate (FDR) ≤0.01. Relative expressions to the
average of pre-B and immature B control Bap1fl/+ group are used to generate the heat map. Genes are grouped into Clusters I-VI based on their expression pattern
across the two cell types and three genotypes. (E) Gene ontology (GO) enrichment analysis on the genes from the Clusters I-VI described in (D). The top two
enriched biological processes terms per cluster are displayed.April 2021 | Volume 12 | Article 626418
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Cell Genome
To identify the genes directly regulated by BAP1, we mapped the
genome-wide DNA-binding sites of BAP1 by ChIP-Seq. The
experiment was carried out in the B cell precursor cell line Ba/F3:
a) using wild type cells with an anti-BAP1 antibody, and b) using
cells stably expressing 3xFLAG-tagged BAP1 protein with an
antibody against the FLAG epitope (38). We identified a total of
13,163 BAP1 binding sites (or peaks) across the genome, with a
very high concordance between the two datasets (Figure 6A,
Supplemental Table S1E). Ordering the BAP1-binding sites
based on their distance to the nearest gene transcription startFrontiers in Immunology | www.frontiersin.org 11site (TSS), 74% were located within 1kb of the nearest TSS and
were therefore classified as gene-proximal (≤1kb to TSS, 9,680
sites), and the remaining 26% were classified as gene-distal (>1kb
to TSS, 3,483 sites) (Supplemental Table S1E). To gain
functional insight into the transcriptional targets of BAP1 in B
cells, gene ontology analysis was performed on the genes in the
vicinity of each BAP1 binding site using the Genomic Regions
Enrichment of Annotations Tool (GREAT) (69). This
demonstrated that the genes near the gene-proximal BAP1
binding sites were highly enriched for biological process
ontology terms “cell cycle” and “DNA metabolic process”





FIGURE 5 | Impaired proliferation in CRISPR/Cas9 BAP1-deficient B cell precursor cell line Ba/F3. (A) gRNA targeted cleavage on Bap1 gene sequence. gRNA1
and gRNA2 were designed to target exons 4 and 5 of mm9 Bap1 gene, respectively. The gRNA-targeted DNA fragments of exons 4 and 5, as well as the
corresponding amino acids of BAP1 protein are displayed in detail. Arrows indicate predicted sites of Cas9 mediated double strand break (DSB). Both the cleavage
sites are upstream of the key catalytic residue of BAP1 protein Cys-91 (red). (B) Loss of BAP1 protein expression in Bap1D/D cell line clones 1-6, demonstrated with
Western blotting, using b-Actin as the loading control. Additional clone with residual BAP1 expression, analyzed on the gel between clones 2 and 3, was excluded
from subsequent analysis. (C) Cell viability analysis with flow cytometry, staining the cells with Annexin V and Viability Dye, to identify live (AnxV-V506-), early
apoptotic (AnxV+V506-), and late apoptotic/necrotic (AnxV+V506+) cells; consolidated data from 6 Bap1D/D cell clones is presented. (D) Cell proliferation analysis with
colorimetric alamarBlue assay, demonstrating reduced proliferation of Bap1D/D cell clones. Data presented in from one experiment and was reproduced in a second
independent experiment. (E) Cell proliferation analyses with a flow cytometry based CFSE-dilution assay, gating on live cells. Consolidated data from two
independent experiments is presented, normalizing the CFSE mean fluorescence intensity (MFI) of Bap1D/D cell clones in each experiment to their corresponding WT
control. In (C–E), bars represent mean ± SEM; statistical analyses were performed using ANOVA; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, or not
significant if significance is not indicated. (F) Representative histograms showing CFSE fluorescence of WT and Bap1D/D clones KO3 and KO4, at 22 hours of
culture, gating on live cells. A histogram showing CFSE fluorescence of WT cells prior to culture (0 hours, dotted line) is included as a positive control.April 2021 | Volume 12 | Article 626418





FIGURE 6 | ChIP-Seq analysis of BAP1 binding sites, and the impact of BAP1 loss on histone H2AK119ub levels, in the B cell precursor cell line Ba/F3. (A) Heat
map showing the tag density of 13,163 BAP1 binding sites identified in ChIP-Seq experiments from wild type Ba/F3 B cell lineage precursor cells (WT) and Ba/F3
cells stably expressing triple-FLAG-tagged BAP1 (FLAG x3). The sites are ranked based on their distance to the nearest gene transcriptional start site (TSS). Gene-
proximal sites are defined as having the nearest gene TSS within 1kb, and gene-distal sites are defined as having the nearest gene TSS further than 1kb. (B) Gene
Ontology analysis of the nearest genes to each BAP1 binding site, performed on the GREAT website (69). The -log10(binomial FDR) value for each term is plotted.
(C, D) Histograms showing the average normalized tag densities of BAP1 and histone H2AK119ub around the gene-proximal (C) and gene-distal (D) BAP1 binding
sites. The tag densities of BAP1 are determined from the ChIP-Seq data of WT and FLAG x3 Ba/F3 cells, and the tag densities of histone H2AK119ub are from the
ChIP-Seq data of WT and two Bap1D/D (KO) Ba/F3 cells lines. (E) Venn diagram comparing the BAP1 binding sites identified in our ChIP-Seq datasets from B cells
with BAP1 binding sites identified in previous studies in ES-cells and macrophages (38, 75). (F) Analyses of the co-localization of BAP1 binding sites identified in our
ChIP-Seq data with the binding sites for other functionally related transcriptional regulators in previously published studies. Heatmap displaying the Spearman rank
correlations between all pairwise comparisons for the BAP1 ChIP-Seq data and the ChIP-Seq datasets of other functionally related transcriptional regulators.
Spearman correlations were calculated using the normalized tag densities ( ± 100bp around peak summit) across the entire set of binding sites identified from the
ChIP-Seq experiments. The BAP1 ChIP-Seq from Ba/F3 cells represents our datasets and is described in (A, B). The others are public datasets, downloaded and
re-analyzed using our pipeline. These include the BAP1 ChIP-Seq from ES cells (75), the BAP1, HCF1, and OGT ChIP-Seq from bone marrow derived macrophages
(38), the ASXL1 ChIP-Seq from c-Kit+ bone marrow cells (76), the RING1B, CBX7, EZH2, and USP16 ChIP-Seq from quiescent CD43- resting splenic B cells (17),
and the YY1 ChIP-Seq from follicular B cells (CD19+AA4-CD21loCD23hi) (77); all datasets are from mouse.Frontiers in Immunology | www.frontiersin.org April 2021 | Volume 12 | Article 62641812
Lin et al. BAP1 in B Lymphocyte Developmentinvolvement of BAP1 in the regulation of the transcriptional
programs required for B cell proliferation.
BAP1 Functions as a Deubiquitinase for
Histone H2AK119ub in B Cells
To gain insights into the mechanisms of BAP1 transcriptional
and epigenetic regulation in the B cell lineage, we performed
ChIP-Seq analysis for the repressive histone mark H2AK119ub,
comparing the Bap1D/D and control Ba/F3 B cell precursor cell
lines. Two clones of Bap1D/D cells were selected, KO3 and KO4,
based on full loss of BAP1 protein and a proliferation defect
representing an average of that seen across all the available clones
(Figures 5D, E). The ChIP-Seq data demonstrated that on
average the genomic regions surrounding the BAP1 binding
sites had low levels of histone H2AK119ub in wild type Ba/F3
cells, consistent with their predominant localization at promoters
of expressed genes (Figures 6C, D). Importantly, the levels of
histone H2AK119ub at these BAP1-bound genomic sites were
significantly elevated in Bap1D/D relative to wild-type cells
(Figures 6C, D, Supplemental Figure S7B). This indicated the
non-redundant role of BAP1 as a deubiquitinase for histone
H2AK119ub in the B cell lineage, as previously also reported for
other cell types (27–30).
To compare the roles of BAP1 in transcriptional regulation in
B cells and other cell types, we consolidated our BAP1 ChIP-Seq
and previously published BAP1 ChIP-Seq datasets, with
macrophages and ES cells being the source of the available data
(38, 75). Spearman rank correlation analysis was performed for
all pairwise comparisons. The results demonstrate a considerable
overlap in the genomic location of BAP1 binding across the cell
types, and also highlight a subset of BAP1 binding sites
potentially specific to B cells (Figures 6E, F, Supplemental
Figures S7C–D, full lists of sites available in Supplemental
Table S1E). Genes nearest to each of the “shared” and the
“cell-type specific” subsets of BAP1 binding sites were further
analyzed for enrichment of biological process GO-terms,
demonstrating shared BAP1 binding at the genes involved in
many housekeeping biological processes, including “cell-cycle”,
across the different cell lineages (Supplemental Figure S7C).
To gain mechanistic insights into BAP1 cross-talk with other
transcriptional regulators, we further consolidated our BAP1
ChIP-Seq with ChIP-Seq datasets for BAP1-associated
transcriptional regulators ASXL1 (27–30), HCF1 (31–34), OGT
(37, 38), and YY1 (33), for components of PRC complexes
RING1B, CBX7, and EZH2 (9–11), and with a dataset for
deubiquitinase USP16 (17), using data from murine B cells
(where available) and also datasets from macrophages and
hematopoietic progenitors (17, 38, 76, 78). A significant
correlation in genomic localization was observed between
BAP1 and BAP1-interacting proteins ASXL1, HCF1, YY1 and
to a lesser extent OGT (Figure 6F, Supplemental Figure S7D,
Table S1E), suggesting that BAP1 acts in cooperation with these
proteins in the B cell lineage, as in other cell types (27–34, 37, 38).
Weak correlation was observed between the genomic localization
of BAP1 and the RING1B catalytic subunit of the histone H2A
ubiquitin ligase PRC1, and no correlation was seen with theFrontiers in Immunology | www.frontiersin.org 13PRC2 catalytic subunit EZH2 (Figure 6F, Supplemental Figure
S7D, Table S1E), supporting the antagonistic roles of BAP1 and
PRCs in transcriptional regulation. Interestingly, a positive
correlation was observed between BAP1 and USP16, indicating
that these deubiquitinases may target some common genomic
locations, and suggesting cooperative or complementary
functions (Figure 6F, Supplemental Figure S7D, Table S1E).
Exploring BAP1 Regulated Transcriptional
Programs in B Cell Development
We consolidated our ChIP-Seq and RNA-Seq datasets and
identified in total 591 genes that had BAP1 binding sites in
their proximity and were dysregulated in expression in BAP1
deficiency (Supplemental Table S1G). Repeating the analysis for
each cluster of genes dysregulated in BAP1-deficient B cells, we
observed a strong and significant overrepresentation of BAP1
binding sites at the genes in the downregulated Clusters IV-VI
(Figure 7A, Figures 4D, E). In particular, the strongest
overrepresentation of genes with BAP1 binding sites was seen
for Cluster V, enriched for the genes involved in cell cycle
progression and downregulated in expression in BAP1-
deficient pre-B cells (Figure 7A, Figures 4D, E). Overall, this
demonstrates a strong concordance between our RNA-Seq and
ChIP-Seq datasets, consistent with the primary function of BAP1
as a transcriptional activator. The strong correlation between
BAP1 occupancy, histone H2AK119ub levels, and gene
expression suggests a direct role of BAP1 in the regulation of
genes essential for normal cell cycle progression in pre-B cells.
Gene ontology (GO) analysis further confirmed that the set of
genes in proximity of BAP1 binding sites and downregulated in
expression in BAP1-deficient pre-B cells was strongly enriched
for GO-terms “cell cycle” and “DNA replication” (Cluster V,
Figure 7B, Supplemental Table S1H). Notably, this gene set
included the key genes encoding: regulators of G1/S cell cycle
transition (Ccne2, Cdc25a) and the initiation of DNA replication
(Cdc6, Cdc45, Cdt1); components of the core DNA replication
machinery (Pola1, Pold1, Pole, Pole2, Pcna, Rfc1, Dna2, Lig1,
Mcm2-7) and enzymes involved in deoxyribonucleotide
synthesis (Rrm1, Rrm2); regulators of G2/M cell cycle
transition (Bub1, Cdc25a, Espl1, Plk1), mitotic spindle
dynamics (Haus4-5, Ndc80, Kif2c, Kif23, Kif11, Kntc1), and
cytokinesis (Anln, Ect2, Prc1); key regulators of chromatin
structure through the S and M phases of the cell cycle (Esco2,
Ncapd2, Ncapg2, Uhrf1); and several general biomarkers of cell
proliferation (Foxm1, Mki67) (Figure 7C, Supplemental Figure
S7E, Table S1G). Overall, our data suggests a direct role of BAP1
in the regulation of the transcriptional programs of cell
proliferation, linked to its requirement for cell cycle
progression in pre-B cells and for normal B cell development.
To gain insights into the putative mechanisms through which
BAP1 may regulate the transcriptional programs of cell cycle
progression in B cell development, we assessed the levels of the
repressive histonemark H2AK119ub in Bap1D/D relative to control
Ba/F3 B cell precursor cell lines from our ChIP-Seq data,
specifically focusing on the BAP1 binding sites within the
promoters Cluster V genes downregulated in expression inApril 2021 | Volume 12 | Article 626418
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FIGURE 7 | BAP1 in the regulation of genes involved in cell proliferation and cell cycle progression in pre-B cells. (A) Consolidation of the RNA-Seq and ChIP-Seq
datasets, described in Figures 4 and 6, showing the percentages of genes dysregulated in expression in Bap1fl/flCre cells with at least one BAP1 binding site within
the indicated range of their TSS. Analysis is performed for each of the Cluster I-VI of the genes dysregulated in Bap1fl/flCre cells, as defined in Figure 4D. The
random genes cluster consists of ten groups of 300 genes randomly selected from 24,421 genes in the mm9 genome. The random binding sites consist of ten
groups of 10,000 genomic locations randomly selected from the mm9 genome. Fisher Exact Test is used to calculate the p-values. (B) Gene ontology (GO)
enrichment analysis for the Clusters I-VI genes, dysregulated in expression in Bap1fl/flCre cells, and containing a proximal or distal BAP1 binding site. Top three
enriched biological process terms per Cluster are displayed. (C) Genomic snapshots of selected genes that represent the putative direct transcriptional targets of
BAP1 in pre-B cells. The genes are selected from Cluster V genes that are downregulated in expression in Bap1fl/flCre pre-B cells, carry a proximal or distal BAP1
binding site, and are functionally linked to cell proliferation and cell cycle progression. ChIP-Seq tracks for BAP1 and input DNA are shown on the top two lanes. The
gene feature track is shown in the middle. Averaged RNA-Seq tracks for pre-B cells are in the bottom three lanes, with fold changes comparing expression levels in
Bap1fl/flCre and control Bap1fl/+ samples indicated. The maximum data range of each track is indicated at the top-right corner of the track. (D) Box plot showing
histone H2AK119ub read intensities ±2.5kb to BAP1 binding sites near putative BAP1-regulated Cluster V genes, functionally linked to cell proliferation and cell cycle
progression; (GO terms: GO:0007049 ~cell cycle; GO:0006260 ~DNA replication; GO:0051301 ~cell division; mmu04110: Cell cycle; and/or mmu03030: DNA
replication, 69 genes in total, Table S1G). The Mann-Whitney U test was used to calculate the p-values. (E) Histograms showing the average normalized read
intensities of BAP1 and histone H2AK119ub at the BAP1 binding sites proximal to the select subset of Cluster V genes, functionally linked to cell proliferation and cell
cycle progression, as specified above. The read intensities of BAP1 are determined from the ChIP-Seq data of WT and FLAG x3 Ba/F3 cells, and the read intensities
of histone H2AK119ub are from the ChIP-Seq data of WT and two Bap1D/D (KO) Ba/F3 cell lines.Frontiers in Immunology | www.frontiersin.org April 2021 | Volume 12 | Article 62641814
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“DNA replication”, and “cell division” (69 genes, Supplemental
Table S1G). Importantly, a significant increase in histone
H2AK119ub levels was observed in Bap1D/D relative to control
cells at these promoters (Figures 7D, E). This strongly suggests
that BAP1 regulates the expression of the genes essential for cell
proliferation and cell cycle progression in B cell development at
least in part via the deubiquitination of histone H2AK119ub.DISCUSSION
In this work, we establish the non-redundant and cell intrinsic
role of BAP1 in the normal progression of B cell development, and
suggest BAP1 as a regulator of the transcriptional programs
required for cell proliferation and cell cycle progression in
pre-B cells, via its deubiquitinase catalytic activity for
histone H2AK119ub.
B cell dysfunction was previously reported by Arenzana et.al.,
following an inducible deletion of Bap1 in the Bap1fl/flCreERT2
mouse model (47), showing a depletion of pre-pro-B, small pre-
B, immature, and mature B cell subsets. It is, however, important
to note the complementarity and the differences between our
experimental systems, with Arenzana et al. analyzing an acute
and systemic loss of BAP1 (38, 47), whereas our current work
assesses BAP1 deletion specifically within the B cell lineage (52).
Such differences likely account for the differential depletion of
the B cell precursor subsets across the two models. Overall, our
work for the first time allows to assess the cell intrinsic role of
BAP1 following B cell lineage commitment, independently of its
role in the earlier hematopoietic progenitor cells or the cells of
the bone marrow niche (38, 47).
The full mechanisms leading to the depletion of large pre-B
cells in Bap1D/D mice remain to be further explored. The crosstalk
between IL7R and pre-BCR signaling is the major regulator of the
balance between large pre-B cell proliferation, their further
differentiation to small pre-B cells, and the subsequent initiation
of Ig light chain rearrangement (79–81). Our study therefore
suggests a possible role for BAP1 as a transcriptional and
epigenetic regulator of cell cycle progression downstream of
IL7R and pre-BCR signaling. Future studies should address
whether Bap1-deficiency impairs the proliferative response of
pro-B and pre-B cells to ex vivo IL7 stimulation (82, 83), and
also test for direct protein interactions between BAP1 and the
components of IL7R and pre-BCR signaling machinery. pre-BCR
signaling and large pre-B cell proliferation are also required to
establish a normal B cell repertoire diversity and for the negative
selection of autoreactive B cell clones (79). The impact of Bap1-
deficiency on repertoire diversity and the negative selection of
autoreactive B cells therefore remains to be further addressed.
While our study links the depletion of large pre-B cells in
Bap1fl/fl mb1-Cre mice to the disruption in cell proliferation and
the direct role of BAP1 in the regulation of genes required for cell
cycle progression, the expansion of Fraction B pro-B cells also
seen in Bap1fl/fl mb1-Cre mice is not linked to changes in cell
cycle or cell survival, and remains to be further explored in futureFrontiers in Immunology | www.frontiersin.org 15work. Similarly, the mechanisms leading to the depletion of
mature B cells in the bone marrow, spleen, and lymph nodes of
Bap1fl/fl mb1-Cre mice remain to be further addressed and may
be distinct from the mechanisms driving the depletion of large
pre-B cells, analyzed in our current study. In particular, the
cross-talk between BAP1 functions in mature B cells and the
BAFF/BAFFR pathway essential for the survival of transitional-2,
follicular and marginal zone B cells (84, 85), and the NOTCH
pathway required for marginal zone B cell development (86),
merit further investigation. Interestingly, the role of BAP1 as a
regulator of NOTCH pathway signaling is already indicated in
other cell types (87). Furthermore, the role of BAP1 in the
development and maintenance of B1 cells is not sufficiently
addressed in our current work, and requires further
investigation, given that B1 cell development is driven by
distinct progenitor cells, occurs in distinct developmental
waves during ontogeny, and is regulated by distinct
transcription factors and gene expression networks (71, 88).
Our work has advanced the understanding of the molecular
functions of BAP1 within the B cell lineage. Our findings suggest
that BAP1 may have a direct role in the regulation of the
transcriptional programs of cell cycle progression in B cell
development. Although our transcriptional analyses of Bap1fl/fl
Cre pre-B cells is somewhat confounded by the depletion of the
more proliferative large pre-B cell subset from the analyzed
cell population, it is important to note that the dysregulation
in cell cycle was observed in both large pre-B and small pre-B cell
subsets that make up the pre-B cell pool sorted for the
transcriptional profiling. Furthermore, there was a highly
significant overrepresentation of BAP1 binding sites in
proximity of the genes dysregulated in our transcriptional data
from Bap1fl/flCre pre-B cells, providing further support for our
conclusions. The overrepresentation of BAP1 binding sites was
especially significant at the downregulated genes involved in cell
proliferation and cycle progression, and the loss of BAP1 resulted
in increased H2AK119ub levels at these sites, supporting a direct
role of BAP1 and its deubiquitinase catalytic activity for histone
H2A in their transcriptional regulation. Overall, we hypothesize
that a disruption in BAP1-regulated transcriptional programs of
cell proliferation and cell cycle progression may contribute to the
defects in B cell development in BAP1-deficiency.
The functional link between the loss of BAP1 and impaired
cell proliferation, suggested for the B cell lineage in our current
work, is shared across several different cell types (32, 34–36, 47).
As already discussed, an inducible systemic deletion of Bap1 in
mice results in impaired proliferation of thymocytes and
peripheral CD4 T cells (47), suggesting shared BAP1 function
across the different cell types of the lymphoid lineage. Depletion
of erythrocytes and platelets was also reported in this model,
however not linked to specific cell proliferation defects (38).
BAP1 was also shown to be essential for proliferation of several
non-hematopoietic cell lines, regulating transcriptional
programs of cell cycle progression in complex with HCF1 (31–
36). Importantly, however, the role of BAP1 as a positive
regulator of cell maintenance and proliferation is not universal,
and Bap1 deletion in mice results in an expansion of myeloidApril 2021 | Volume 12 | Article 626418
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MDS and CMML (38). The apparently opposing roles of BAP1
in the cells of myeloid and lymphoid cell lineages is surprising,
especially as our analyses demonstrate a strong correlation in the
genomic location of BAP1 binding sites across the genome of B
cells, macrophages, and ES-cells (38, 75), suggesting common
transcriptional functions. The mechanisms resulting in the
distinct outcomes of BAP1 loss on the myeloid and lymphoid
cell lineages merit further investigation, and may provide
insights into the functions of BAP1 and its ASXL binding
partners as tumor suppressors (43–45).
We demonstrate that the loss of BAP1 results in an increase in
histone H2AK119ub levels at BAP1 genomic binding sites in B
cell precursor cells, both globally across the genome and also
locally at the promoters of BAP1-target genes involved in the
regulation of B cell proliferation. Overall, this indicates that the
role of BAP1 in the B cell lineage is closely coupled to its activity
as a deubiquitinase for histone H2AK119ub. Deposition of the
repressive histone mark H2AK119ub on chromatin by PRC1 is
traditionally linked to long-term silencing of developmentally
regulated genes, to control the pathways of cellular
differentiation and lineage specification (9–11). More recently
the role of PRC1 and H2AK119ub in the regulation of other
transcriptional programs has emerged, such as the pro-survival
and pro-apoptosis transcriptional programs (89), and the
programs of cell proliferation and cell cycle progression (90–
92) across different cell types. Our findings further highlight the
putative role of the H2AK119ub epigenetic mark and the
machinery that regulates its deposition on and removal from
chromatin in the regulation of the transcriptional programs of
cell proliferation in B lymphocytes.
BAP1 is an important tumor suppressor, and germline BAP1
mutations in human result in a strong predisposition to a range
of cancers, including mesothelioma, uveal melanoma, renal cell
carcinoma, and others (43, 44). Although B cell lymphomas are
not commonly associated with BAP1 mutations, cases of non-
Hodgkin lymphoma have been reported in carriers of germline
BAP1 mutations (93). Furthermore, lymphomas that carry other
genetic aberrations have been shown to acquire BAP1 gene
silencing via epigenetic mechanisms (94). This raises the
possibility that BAP1 may function as a tumor suppressor also
in the B cell lineage. This hypothesis remains to be further tested
in mouse models, for example by screening for the incidence of
spontaneous lymphomas in Bap1fl/fl Cre mice, or by tracking
other age-associated phenotypes and the life-span of the animals.
Future studies will need to further address these questions,
providing insights into potential tumor suppressor functions
and other functions of BAP1 within the B cell lineage.
The molecular mechanisms underlying the tumor suppressor
activities of BAP1 remain controversial, especially in the light of
this and many other reports implicating BAP1 as a positive
regulator of cell proliferation (35). The tumor suppressor activity
of BAP1 in myeloid progenitor cells was linked to its antagonism
with PRC2, as the transformation of BAP1-deficient myeloid
cells was associated with an increase in PRC2-mediatedFrontiers in Immunology | www.frontiersin.org 16transcriptional repression and could be abolished by the loss or
inhibition of the PRC2 catalytic subunit EZH2 (95, 96). Similar
mechanisms are implicated in the tumor suppressor activities of
BAP1 in mesothelioma (95), but not in uveal melanoma cell lines
(97). Other mechanisms linking BAP1 molecular functions and
its tumor suppressor activity are also proposed, including: its
roles in transcriptional regulation of pro-survival and pro-
apoptosis transcriptional programs in cross-talk with PRC1
(89); its role as a positive regulator of ferroptosis via repression
of SLC7A11 gene expression (98); its role in the transcriptional
regulation of cellular metabolic programs (37, 99–101), and in
the regulation of Ca2+ signaling and apoptosis via
deubiquitination and stabilization of receptor-channel IP3R3
(42, 102). We observed that SLC7A11 was not expressed in
pre-B and immature B cells, from either control or Bap1fl/flCre
mice, indicating that the regulation of ferroptosis by BAP1 is
unlikely to play significant physiological role in these B cell
precursor cells. Our data further revealed no significant
correlation in the genomic localization of BAP1 binding sites
and the binding sites of the PRC2 catalytic subunit EZH2 in the B
cell lineage. Future studies will need to further address the
molecular mechanisms underlying the tumor suppressor
activities of BAP1 in different cell types, in the light of its
apparent positive role in the regulation of cell proliferations in
non-transformed cells of many tissues.
We have demonstrated that the loss of BAP1 results in
impaired B lymphocyte development, and suggested the link of
this phenotype to the altered transcriptional profile and the
defects in proliferation in BAP1-deficient pre-B cells. It is
important to note, however, that BAP1 remains expressed
throughout the B cell lineage, and that cell cycle analysis in
Bap1fl/fl Cre mice revealed significant changes not only in pre-B
cells, but also in immature and mature B cells. It is therefore
highly likely that BAP1 remains engaged as an important
transcriptional regulator throughout B cell ontogeny. Cell
proliferation is essential not only for the formation and
maintenance of the pool of naïve B cells, but also for the
normal execution of B cell mediated immune response,
including clonal expansion during the germinal center reaction
(103–105). Future studies should address the cell intrinsic role of
BAP1 in B cells during the execution of humoral immune
response, including the germinal center reaction, and the
differentiation and persistence of plasma and memory B cells.
In summary, our work establishes the non-redundant and cell
intrinsic role of BAP1 in B cell development. It further suggests a
direct role of BAP1 in the induction of the transcriptional
programs of cell proliferation and cell cycle progression in pre-
B cells, linked to its catalytic function as a deubiquitinase for
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